Seller record · Telehealth service

Maves

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S4, compounding disclosure: The semaglutide page sells a product compounded in the United States and answers whether it is safe by saying semaglutide is FDA-approved for metabolic and weight-related conditions. No page states that the compounded medications are not FDA-approved. 2 more criteria also fail; see the table below.

At a glance

MavesTelehealth service

5/8criteria passed

Price: Semaglutide $89 first month, then $189 a month; tirzepatide $184 first month, then $284
Sells: compounded semaglutide, compounded tirzepatide, sermorelin, and 1 more
FDA letters: None on file

Visit Maves See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A men's performance telehealth brand selling compounded semaglutide and tirzepatide for fat loss, plus sermorelin and NAD+ injections, with care from contracted medical groups. Care starts with an online health questionnaire, its terms name two partner pharmacies, and the site prints no legal name or address of its own.

Operating entity No legal entity name for Maves appears in the footer, on the contact or about pages, in the terms of service or in the privacy policy; the terms and the privacy policy name a different company as the operator of a different website.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Maves' semaglutide product page; Maves' terms of service page
S2	Prescription gating	PASS	Maves' semaglutide product page; Maves' terms of service page
S3	Pharmacy identification	PASS	Maves' terms of service page
S4	Compounding disclosure	FAIL	Maves' semaglutide product page; Maves' safety information page
S5	Analytical documentation	FAIL	Maves' semaglutide product page
S6	Business address	FAIL	Maves' contact page; Maves' terms of service page; Maves' privacy policy
S7	Price disclosure	PASS	Maves' semaglutide product page; Maves' tirzepatide product page; Maves' sermorelin product page; Maves' NAD+ injection product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed medical provider reviews each health questionnaire and creates a treatment plan only if appropriate, and the terms name the medical groups whose clinicians provide care.Source: Maves' semaglutide product page; Maves' terms of service page.

S2PASSThe product pages set out the order as an online health questionnaire reviewed by a licensed provider first, then delivery only if prescribed, and the terms say the plan fee is agreed during checkout as part of the online visit.Source: Maves' semaglutide product page; Maves' terms of service page.

S3PASSThe terms name the partner pharmacies: GoGoMeds, operated by Specialty Medical Drugstore, LLC at 525 Alexandria Pike, Suite 100, Southgate, KY 41071, and Red Rock Pharmacy, with no address given for the second.Source: Maves' terms of service page.

S4FAILThe semaglutide page sells a product compounded in the United States and answers whether it is safe by saying semaglutide is FDA-approved for metabolic and weight-related conditions. No page states that the compounded medications are not FDA-approved.Source: Maves' semaglutide product page; Maves' safety information page.

S5FAILNo certificate of analysis or lot document is published. The product pages say every treatment undergoes third-party testing for purity and potency, with no document behind the claim.Source: Maves' semaglutide product page.

S6FAILNo business address for Maves appears in the footer, on the contact or about pages, in the terms or in the privacy policy. The terms print only the Houston office of the medical group that provides care and the address of a partner pharmacy.Source: Maves' contact page; Maves' terms of service page; Maves' privacy policy.

S7PASSEach product page prints a first month price and the monthly price after it: compounded semaglutide $89 for the first month, then $189 a month; compounded tirzepatide $184, then $284; sermorelin $120, then $160; and NAD+ injections $149, then $169. The menu advertises GLP-1 treatments from $99 for the first month.Source: Maves' semaglutide product page; Maves' tirzepatide product page; Maves' sermorelin product page; Maves' NAD+ injection product page.

S8PASSNo FDA warning letter names Maves, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sermorelin, NAD+ injections.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+

Visit Maves

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.